Drug Interaction Report

Buprenorphine and Safinamide: Interaction Details

AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Buprenorphine

Belbuca Brixadi Buprenex BuTrans Simbadol Sublocade Zorbium
+

Safinamide

Xadago
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Jul 2, 2026
LinkedIn
Interaction severity
Contraindicated
These should generally not be used together.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 633 documented Buprenorphine interactions, 22 are rated contraindicated — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
At a glance + Effects may be stronger
The Bottom Line
Buprenorphine and safinamide should not be used together because of the risk of life-threatening serotonin syndrome; allow at least 14 days after stopping safinamide before starting an opioid, and let your care team choose a safer plan.

Taking these two together is not recommended. Safinamide (Xadago) is a Parkinson's medicine that belongs to a group called MAO inhibitors. Buprenorphine is an opioid pain and addiction medicine. When they are combined, both can raise serotonin, a chemical in your body. Too much serotonin can cause a serious problem called serotonin syndrome.

Warning signs include agitation, a fast heartbeat, sweating, shaking, muscle stiffness, and confusion. This can be dangerous, so this combination is one doctors avoid. Please don't stop or change either medicine on your own. Talk with your pharmacist or doctor, who can pick a safer plan for you.

Contraindicated combination. Safinamide is a selective MAO-B inhibitor; buprenorphine is a partial opioid agonist with serotonergic activity. Concurrent use produces additive serotonergic effects, creating risk of life-threatening serotonin syndrome (reported, evidence graded probable).

  • Direction: additive/pharmacodynamic, not a prodrug or CYP-based interaction.
  • Management: avoid coadministration. Allow at least 14 days after discontinuing safinamide before initiating an opioid.
  • Monitor for: autonomic instability (tachycardia, hyperthermia, diaphoresis), neuromuscular signs (clonus, hyperreflexia, rigidity), and altered mental status.

Choose a non-serotonergic analgesic alternative in consultation with the prescriber.

Onset
unspecified
Evidence
probable
Severity
Contraindicated

What happens

Increased risk of serotonin syndrome

Interaction Deep Dive

The combined use of an opioid with safinamide, which functions as an MAO type B inhibitor, is contraindicated because of the risk of serotonin syndrome, a condition that can be life-threatening and has been documented. A minimum of 14 days should elapse following the cessation of safinamide before an opioid is started1.

Why it happens (mechanism)

Additive serotonergic effects

How to manage this interaction

Because this combination can trigger serotonin syndrome, care teams generally avoid using them together.

  • If safinamide is being stopped, the guidance is to wait at least 14 days before starting an opioid like buprenorphine.
  • Your team may choose a different, non-serotonergic pain option instead.

What you should do: Keep taking your medicines as prescribed and do not stop either one on your own. Tell your pharmacist or prescriber that you have been prescribed both, and get urgent help for symptoms like agitation, fast heartbeat, sweating, shaking, muscle stiffness, or confusion.

Management is individual — confirm any change with your pharmacist or prescriber.

Literature reports

1 report — tap to read

a) Instances of serotonin syndrome have been documented when a MAOI (including selective MAOI type B) is used together with opioids 1.

Common questions

Can I take Buprenorphine and Safinamide together?

Buprenorphine and safinamide should not be used together because of the risk of life-threatening serotonin syndrome; allow at least 14 days after stopping safinamide before starting an opioid, and let your care team choose a safer plan. Always confirm with your pharmacist or prescriber before making any change.

How serious is the Buprenorphine and Safinamide interaction?

It is rated contraindicated. These should generally not be used together.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How is the Buprenorphine and Safinamide interaction managed?

Because this combination can trigger serotonin syndrome, care teams generally avoid using them together. If safinamide is being stopped, the guidance is to wait at least 14 days before starting an opioid like buprenorphine. Your team may choose a different, non-serotonergic pain option instead. What you should do: Keep taking your medicines as prescribed and do not stop either one on your own. Tel… Management is individual — always follow your own care team's guidance.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Questions for your pharmacist

  • Does my dose of Buprenorphine or Safinamide need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (1)

  1. Product Information: XADAGO(R) oral tablets, safinamide oral tablets. US WorldMeds, LLC (per FDA), Louisville, KY, 2017. DailyMed
Was this write-up helpful?
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.